Skip to main content

Pharvaris

CLINICAL PIPELINE

Pharvaris is committed to developing new oral treatments for bradykinin-mediated angioedema (AE-BK). Our pipeline is anchored by deucrictibant, the only orally administered bradykinin B2 receptor antagonist currently in clinical development, to our knowledge.

Molecule
Deucrictibant is an investigational oral bradykinin B2 receptor antagonist
Indication

Deucrictibant immediate-release capsule rapidly reaches therapeutic exposure within 15-20 minutes,1 making it optimal for on-demand oral treatment of HAE attacks.

Pre-Ind

development cycle
Phase 1
Phase 2
Phase 3

LTE

Registrational

Deucrictibant extended-release tablet maintains sustained therapeutic exposure over 24 hours2 from day one, allowing for once-daily oral treatment to prevent HAE attacks.

Pre-Ind
development cycle
Phase 1
Phase 2
Phase 3
OLE
Registrational
Acquired angioedema due to C1 inhibitor deficiency is a type of bradykinin-mediated angioedema.
Pre-Ind
development cycle
Phase 1
Phase 2
Phase 3
Registrational
pipeline
Molecule
Indication
Pre-IND
Phase 1
Phase 2
Phase 3
Registrational

Deucrictibant is an investigational oral bradykinin B2 receptor antagonist.

primary and all
secondary endpoints met
Ongoing

Phase 3 study
Ongoing Phase 2/3

open-label extension study
primary endpoints met
Ongoing

Phase 3 study
Ongoing Phase 3 open-label

extension study

Expanded Access Program

Pharvaris is committed to improving treatment and health-related quality of life for people living with bradykinin-mediated angioedema and other bradykinin-mediated conditions through innovative research, discovery, development, and manufacturing of novel therapeutics.
Learn more about our approach to expanded access program.
Learn more about our approach

Publications

Learn more about our scientific discoveries in our latest publications
explore publications

Patent Library

Learn more
References

Aygoren-Pursun E, et al. Lancet Hematol. 2026. | CHAPTER-1 NCT05047185. | CHAPTER-3 NCT06669754. | CHAPTER-4 NCT06679881. | CREAATE NCT07266805. | Maurer M, et al. Lancet Haematol. 2026. | On-Demand Expanded Access Program NCT07759141. | RAPIDe-1 NCT04618211. | RAPIDe-2 NCT05396105. | RAPIDe-3 NCT06343779. | Riedl MA, et al. AAAAI. 2026.